Overcoming Multidrug Resistance in Prostate Cancer: Insights from Orally Bioavailable mSWI/SNF PROTACs and ABCB1 Inhibition

Study Background and Research Question

Epigenetic dysregulation has emerged as a central theme in cancer biology, particularly in enhancer-driven malignancies such as prostate cancer. The mammalian switch/sucrose nonfermentable (mSWI/SNF) complex, a multi-subunit chromatin remodeling machinery, plays a pivotal role in regulating gene expression through chromatin accessibility. Key ATPase subunits within this complex, SMARCA2 and SMARCA4, have been implicated as therapeutic targets for their role in sustaining oncogenic transcription programs. Recent advances in proteolysis-targeting chimera (PROTAC) technology have enabled the targeted degradation of previously 'undruggable' proteins, but resistance mechanisms remain poorly characterized. This study sought to develop an orally bioavailable mSWI/SNF ATPase degrader and investigate acquired resistance pathways, with a particular focus on the role of P-glycoprotein (ABCB1)-mediated drug efflux.

Key Innovation from the Reference Study

The reference paper reports the development of AU-24118, the first orally bioavailable PROTAC degrader capable of targeting both SMARCA2 and SMARCA4 ATPase subunits, as well as PBRM1, in the mSWI/SNF complex. Unlike previous intravenous-only formulations, AU-24118 demonstrates robust pharmacokinetics, antitumor efficacy in castration-resistant prostate cancer (CRPC) models, and a favorable safety profile in preclinical studies (reference study). Furthermore, the study investigates and defines two distinct mechanisms of acquired resistance to such targeted therapies: (1) mutations in the SMARCA4 bromodomain and (2) overexpression of the ABCB1 gene encoding P-glycoprotein (P-gp), an ATP-dependent efflux pump responsible for multidrug resistance (MDR) in cancer.

Methods and Experimental Design Insights

The research utilized a combination of in vitro and in vivo models to characterize the antitumor activity and pharmacokinetics of AU-24118. Prostate cancer cell lines and xenograft mouse models were treated with AU-24118, both as a single agent and in combination with enzalutamide, a standard androgen receptor antagonist. To probe resistance mechanisms, cancer cell lines were subjected to prolonged exposure to high concentrations of AU-24118, followed by genomic and transcriptomic analyses to identify mutations and gene expression changes. Functional assays were conducted to evaluate the impact of SMARCA4 mutations and ABCB1 overexpression on drug sensitivity. Critically, the study tested whether pharmacological inhibition of P-gp with zosuquidar (LY335979) could reverse acquired resistance to PROTAC degraders.

Protocol Parameters

• PROTAC treatment: AU-24118 administered orally in mice; dosing regimens and concentrations adjusted for pharmacokinetic optimization as described in the reference study.
• Resistance induction: Long-term, high-dose exposure of prostate cancer cell lines to AU-24118, followed by clonal selection and molecular characterization.
• P-gp inhibition: Zosuquidar (LY335979) used at concentrations effective for ABCB1 inhibition (e.g., low micromolar range, as supported by product information), to assess reversal of MDR phenotypes.
• Combination studies: Co-administration of AU-24118 and enzalutamide in CRPC models to evaluate additive or synergistic effects on tumor regression.

Core Findings and Why They Matter

AU-24118 demonstrated potent antitumor efficacy in both cell-based and xenograft models of prostate cancer, achieving significant tumor regression and enhanced effects when combined with enzalutamide (reference study). Pharmacokinetic analyses affirmed oral bioavailability and a favorable safety profile in mice and rats. Mechanistically, the study identified two major modes of acquired resistance: point mutations in the SMARCA4 bromodomain, which conferred specific resistance to mSWI/SNF ATPase degraders, and ABCB1 overexpression, which imparted broad resistance to diverse PROTAC degraders including those targeting bromodomain-containing protein 4 (BRD4) and androgen receptor (AR). Notably, ABCB1 upregulation led to increased P-gp activity and reduced intracellular PROTAC concentrations, a classic mechanism underlying multidrug resistance (MDR) in cancer.

Importantly, the application of zosuquidar, a potent and selective P-gp inhibitor, fully restored sensitivity to all tested PROTAC degraders in ABCB1-overexpressing cells, but not in those harboring SMARCA4 mutations. This finding underscores the therapeutic potential of combining PROTAC-based targeted therapies with P-gp inhibition to circumvent ABCB1-mediated resistance. The results carry broad implications for clinical translation, as acquired MDR is a major limitation of many small molecule and targeted therapies in oncology.

Comparison with Existing Internal Articles

The present study builds upon and extends concepts discussed in several internal resources. For example, the article "Oral mSWI/SNF PROTACs and ABCB1-Mediated Resistance in Prostate Cancer" similarly highlights the synergistic potential of combining P-gp inhibition with targeted degradation strategies to overcome resistance in prostate cancer models. In addition, workflow-focused resources such as "Reliable Reversal of Multidrug Resistance with Zosuquidar" provide practical guidance for integrating selective P-gp inhibitors like zosuquidar into laboratory protocols for MDR research. These articles collectively support the translational significance of the current findings, emphasizing the need for robust, reproducible assays to evaluate drug efflux and resistance reversal in cancer drug development.

Further, mechanistic overviews provided in "Zosuquidar (LY335979) 3HCl: Selective P-gp Inhibitor for..." and explorations of tissue distribution and pharmacokinetics in "Zosuquidar (LY335979) 3HCl: Advancing MDR Reversal in Cancer" reinforce the rationale for combining PROTAC therapies with MDR modulators in both preclinical and clinical research workflows.

Limitations and Transferability

While the development of orally bioavailable mSWI/SNF ATPase degraders like AU-24118 represents a substantial advancement, several limitations warrant consideration. First, the study's preclinical focus means that pharmacokinetic and safety profiles require validation in human subjects. Second, resistance mechanisms beyond SMARCA4 mutations and ABCB1 overexpression may emerge in more genetically diverse or treatment-refractory tumors. Third, while zosuquidar effectively restored drug sensitivity in vitro and in vivo, its clinical translation will depend on optimizing dosing, minimizing off-target effects, and understanding potential interactions with other chemotherapeutic agents.

The findings are most directly transferable to settings where MDR is driven by P-gp overexpression, a common feature in advanced prostate cancer and other solid tumors. However, their generalizability to cancers lacking ABCB1 upregulation or with alternative resistance pathways may be limited. Further work is also needed to explore the long-term safety and efficacy of combining MDR modulators with PROTAC-based therapies in clinical populations.

Research Support Resources

Researchers investigating multidrug resistance (MDR) in cancer and the efficacy of targeted degraders can leverage selective P-glycoprotein inhibitors to enhance experimental rigor and clinical relevance. Zosuquidar (LY335979) 3HCl (SKU A3956) from APExBIO is a well-characterized, potent P-gp modulator suitable for in vitro and in vivo studies. Its use at low micromolar concentrations is supported by both product documentation and published literature to effectively inhibit ABCB1-mediated efflux and restore sensitivity to diverse chemotherapeutics and targeted agents. For detailed workflow recommendations and assay optimization strategies, consult recent literature and scenario-driven internal articles that address MDR reversal and P-gp inhibition in cancer research.